EGFR and pancreatic neoplasm: The cell cytotoxicity of the aptamer–gemcitabine hybrid to the EGFR-positive pancreatic cancer cell line, MiaPaCa-2, has increased significantly but not to the EGFR-negative cell line, HPAF-II (Ray et al., 2012).